Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: A. Menarini – Industrie Farmaceutiche Riunite – s.r.l., Via Sette Santi 3, 50131 Florence, Italy
Quofenix 450 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Beige to mottled beige, oblong biconvex tablets of approximately 10 mm width x 21 mm length. |
Each tablet contains delafloxacin meglumine equivalent to 450 mg delafloxacin.
Excipient(s) with known effect: Each tablet contains 39 mg of sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Delafloxacin |
Delafloxacin inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II), enzymes required for bacterial DNA replication, transcription, repair, and recombination. |
| List of Excipients |
|---|
|
Cellulose, microcrystalline |
Laminated aluminium/aluminium foil blisters.
Pack sizes of 10, 20, 30, 50, 60 or 100 tablets.
Not all pack sizes may be marketed.
A. Menarini – Industrie Farmaceutiche Riunite – s.r.l., Via Sette Santi 3, 50131 Florence, Italy
EU/1/19/1393/002-007
Date of first authorisation: 16 December 2019
| Drug | Countries | |
|---|---|---|
| QUOFENIX | Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
